and IBS (Irritable Bowel Syndrome) in childhood. Rifaximin has already been successfully used in adults with SIBO and IBS. Aim: To assess the SIBO prevalence and symptoms improvement in IBS ...
The primary endpoint (patient-reported "adequate relief" of IBS symptoms during at least 2 of the 4 weeks following treatment) was noted by 41% of rifaximin recipients and by 32% of placebo ...
Rifaximin is a semi-synthetic derivative of ... Half-life: 5.6 hours (healthy patients); 6 hours (IBS-D patients).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results